Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ischemic Heart Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 95 articles:
HTML format



Single Articles


    May 2022
  1. FEARON WF, Zimmermann FM, Pijls NHJ
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. Reply.
    N Engl J Med. 2022;386:1865-1866.
    PubMed    


  2. FERLINI M, Munafo A, Visconti LO
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1865.
    PubMed    


  3. FELDMAN D, Nicolas J, Dangas G
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864-1865.
    PubMed    


  4. ROSENBLUM AL, Pack QR
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864.
    PubMed    


  5. VAN BELLE E, Patel M, Davies J
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1863-1864.
    PubMed    


  6. YTTERBERG SR, Bhatt DL, Connell CA
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
    N Engl J Med. 2022;386:1768.
    PubMed    


  7. D'AMICO F, Peyrin-Biroulet L, Danese S
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1767-1768.
    PubMed    


  8. LADAK K, Crowther M
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766-1767.
    PubMed    


  9. OZDEDE A, Yazici H
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766.
    PubMed    


    April 2022
  10. PITT B, Joseph A, Schloemer P
    Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
    N Engl J Med. 2022;386:e43.
    PubMed    


  11. ORTIZ A, Sarafidis P, Ferro CJ
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  12. GERARD AO, Laurain A, Esnault VLM
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  13. KAO PH, Hsu LC
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  14. INGELFINGER JR
    Childhood Risk Factors and Prediction of Adult Cardiovascular End Points.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMe2203743.
    PubMed    


  15. JACOBS DR JR, Woo JG, Sinaiko AR, Daniels SR, et al
    Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMoa2109191.
    PubMed     Abstract available


    March 2022
  16. MAUROVICH-HORVAT P, Bosserdt M, Kofoed KF, Rieckmann N, et al
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022 Mar 4. doi: 10.1056/NEJMoa2200963.
    PubMed     Abstract available


  17. DEVEREAUX PJ, Lamy A, Chan MTV, Allard RV, et al
    High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.
    N Engl J Med. 2022;386:827-836.
    PubMed     Abstract available


    February 2022
  18. PFEFFER MA, Jering KS, Braunwald E
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2022;386:603.
    PubMed    


  19. IOANNOU A
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2022;386:603.
    PubMed    


    January 2022
  20. YTTERBERG SR, Bhatt DL, Mikuls TR, Koch GG, et al
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:316-326.
    PubMed     Abstract available


  21. FEARON WF, Zimmermann FM, De Bruyne B, Piroth Z, et al
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:128-137.
    PubMed     Abstract available


    December 2021

  22. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:2592.
    PubMed    


  23. DESCH S, Freund A, Akin I, Behnes M, et al
    Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
    N Engl J Med. 2021;385:2544-2553.
    PubMed     Abstract available


  24. NEAL B, Tian M, Wu Y
    Salt Substitute and Cardiovascular Events and Death. Reply.
    N Engl J Med. 2021;385:2493-2494.
    PubMed    


  25. BURSZTYN M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2493.
    PubMed    


  26. MORITA H, Komuro I
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492-2493.
    PubMed    


  27. ZUCCALA G, Laudisio A, Ciaburri M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492.
    PubMed    


  28. GRAUDAL N, Jurgens G, Alderman MH
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2491-2492.
    PubMed    


    November 2021
  29. MATHEW R, Di Santo P, Hibbert B
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. Reply.
    N Engl J Med. 2021;385:2108-2109.
    PubMed    


  30. GIBSON LE, Chang MG, Berra L
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2108.
    PubMed    


  31. POTTER BJ
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2107-2108.
    PubMed    


  32. MA Y, He FJ, Sun Q, Yuan C, et al
    24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2021 Nov 13. doi: 10.1056/NEJMoa2109794.
    PubMed     Abstract available


  33. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:1845-1855.
    PubMed     Abstract available


  34. SINGH AK, Carroll K, McMurray JJV, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113380.
    PubMed     Abstract available


  35. SINGH AK, Carroll K, Perkovic V, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113379.
    PubMed     Abstract available


    October 2021
  36. VALGIMIGLI M, Frigoli E, Heg D, Tijssen J, et al
    Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
    N Engl J Med. 2021;385:1643-1655.
    PubMed     Abstract available



  37. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    N Engl J Med. 2021;385:1632.
    PubMed    


    August 2021
  38. NEAL B, Wu Y, Feng X, Zhang R, et al
    Effect of Salt Substitution on Cardiovascular Events and Death.
    N Engl J Med. 2021 Aug 29. doi: 10.1056/NEJMoa2105675.
    PubMed     Abstract available


  39. PITT B, Filippatos G, Agarwal R, Anker SD, et al
    Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2021 Aug 28. doi: 10.1056/NEJMoa2110956.
    PubMed     Abstract available


  40. JONES WS, Wruck LM, Hernandez AF
    Aspirin Dosing in Cardiovascular Disease. Reply.
    N Engl J Med. 2021;385:765.
    PubMed    


  41. JAVOR E, Skelin M, Lucijanic M
    Aspirin Dosing in Cardiovascular Disease.
    N Engl J Med. 2021;385:764-765.
    PubMed    


  42. SACRISTAN JA
    Aspirin Dosing in Cardiovascular Disease.
    N Engl J Med. 2021;385:764.
    PubMed    


  43. MONACH PA, Branch-Elliman W
    Aspirin Dosing in Cardiovascular Disease.
    N Engl J Med. 2021;385:764.
    PubMed    


  44. KALYANI RR
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. Reply.
    N Engl J Med. 2021;385:671-672.
    PubMed    


  45. DONNELLY PE, Winch DE
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    N Engl J Med. 2021;385:670-671.
    PubMed    


  46. BOUSSAGEON R, Maynie-Francois C
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    N Engl J Med. 2021;385:670.
    PubMed    


  47. INZUCCHI SE, Peixoto AJ, Testani JM
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    N Engl J Med. 2021;385:669-670.
    PubMed    


  48. KADIRE SR, Udelson J, Budoff MJ
    Imaging in Coronary Artery Disease Risk Stratification.
    N Engl J Med. 2021;385:655-657.
    PubMed    


  49. MATHEW R, Di Santo P, Jung RG, Marbach JA, et al
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:516-525.
    PubMed     Abstract available


    July 2021
  50. JENKINS DJA, Dehghan M, Yusuf S
    Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. Reply.
    N Engl J Med. 2021;385:379-380.
    PubMed    


  51. KANTER M, Angadi S, Slavin J
    Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
    N Engl J Med. 2021;385:378-379.
    PubMed    


  52. LEOW MK, Henry CJ
    Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
    N Engl J Med. 2021;385:378.
    PubMed    


  53. JUNI P
    PCI for Nonculprit Lesions in Patients with STEMI - No Role for FFR.
    N Engl J Med. 2021;385:370-371.
    PubMed    


  54. VARELA DL, Jones TL
    Perivalvular Abscess Causing Coronary-Artery Compression.
    N Engl J Med. 2021;385:e3.
    PubMed    


    June 2021
  55. GERSTEIN HC, Sattar N, Rosenstock J, Ramasundarahettige C, et al
    Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
    N Engl J Med. 2021 Jun 28. doi: 10.1056/NEJMoa2108269.
    PubMed     Abstract available


  56. LAU ES, Scirica B, Schaefer IM, Miller AL, et al
    Hypertensive Heartbreak.
    N Engl J Med. 2021;384:2145-2152.
    PubMed    


    May 2021
  57. LOFFI M, Danzi GB
    Isolated Coronary Artery.
    N Engl J Med. 2021;384:e79.
    PubMed    


  58. BLANCO-DOMINGUEZ R, Sanchez-Diaz R, de la Fuente H, Jimenez-Borreguero LJ, et al
    A Novel Circulating MicroRNA for the Detection of Acute Myocarditis.
    N Engl J Med. 2021;384:2014-2027.
    PubMed     Abstract available


  59. YEKU OO, Medford AJ, Fenves AZ, Uljon SN, et al
    Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
    N Engl J Med. 2021;384:1943-1950.
    PubMed    


  60. PUYMIRAT E, Cayla G, Simon T, Steg PG, et al
    Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.
    N Engl J Med. 2021 May 16. doi: 10.1056/NEJMoa2104650.
    PubMed     Abstract available


  61. JONES WS, Mulder H, Wruck LM, Pencina MJ, et al
    Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
    N Engl J Med. 2021 May 15. doi: 10.1056/NEJMoa2102137.
    PubMed     Abstract available


  62. RODRIGUEZ F, Harrington RA
    Antithrombotic Therapy after Acute Coronary Syndromes. Reply.
    N Engl J Med. 2021;384:1873-1874.
    PubMed    


  63. PARADA BARCIA J, Raposeiras Roubin S, Abu-Assi E
    Antithrombotic Therapy after Acute Coronary Syndromes.
    N Engl J Med. 2021;384:1873.
    PubMed    


  64. BITTL JA
    Antithrombotic Therapy after Acute Coronary Syndromes.
    N Engl J Med. 2021;384:1872-1873.
    PubMed    


  65. KONIG MF, Sathiyakumar V, Phan CM, Schulman SP, et al
    Inside and Out.
    N Engl J Med. 2021;384:1753-1760.
    PubMed    


    April 2021
  66. YUSUF S, Joseph P, Pais P
    Polypill in Persons without Cardiovascular Disease. Reply.
    N Engl J Med. 2021;384:1676-1677.
    PubMed    


  67. CAINZOS-ACHIRICA M
    Polypill in Persons without Cardiovascular Disease.
    N Engl J Med. 2021;384:1675-1676.
    PubMed    


  68. WALD N, Wald D, Law M
    Polypill in Persons without Cardiovascular Disease.
    N Engl J Med. 2021;384:1675.
    PubMed    


  69. MESSERLI FH, Brguljan J, Bangalore S
    Polypill in Persons without Cardiovascular Disease.
    N Engl J Med. 2021;384:1674-1675.
    PubMed    


  70. ALAM A, Carey SA, Hall SA
    Polypill in Persons without Cardiovascular Disease.
    N Engl J Med. 2021;384:1674.
    PubMed    


  71. GALLIENI M, Paik JM, Fiorina P
    Polypill in Persons without Cardiovascular Disease.
    N Engl J Med. 2021;384:1673-1674.
    PubMed    


  72. BHATT DL, Steg PG, Pitt B
    Cardiovascular Outcomes with Sotagliflozin. Reply.
    N Engl J Med. 2021;384:1471-1473.
    PubMed    


  73. MARCHAND L, Villar E, Green L
    Cardiovascular Outcomes with Sotagliflozin.
    N Engl J Med. 2021;384:1471.
    PubMed    


  74. BAGLIONI P
    Cardiovascular Outcomes with Sotagliflozin.
    N Engl J Med. 2021;384:1470-1471.
    PubMed    


  75. KALYANI RR
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    N Engl J Med. 2021;384:1248-1260.
    PubMed    


    March 2021
  76. KIM ESH
    Spontaneous Coronary-Artery Dissection. Reply.
    N Engl J Med. 2021;384:1077-1078.
    PubMed    


  77. WANG X, Ge J
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2021;384:1077.
    PubMed    


  78. CAMPOCHIARO C, Tomelleri A, Dagna L
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2021;384:1077.
    PubMed    


  79. GIBBONS GH, Seidman CE, Topol EJ
    Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress.
    N Engl J Med. 2021;384:785-788.
    PubMed    


    February 2021
  80. FIOLET ATL, Cornel JH, Thompson PL
    Colchicine in Patients with Chronic Coronary Disease. Reply.
    N Engl J Med. 2021;384:778-779.
    PubMed    


  81. D'AMARIO D, Rodolico D, Galli M
    Colchicine in Patients with Chronic Coronary Disease.
    N Engl J Med. 2021;384:778.
    PubMed    


  82. LUCIJANIC M, Javor E, Skelin M
    Colchicine in Patients with Chronic Coronary Disease.
    N Engl J Med. 2021;384:777-778.
    PubMed    


  83. FISCHER BG
    Colchicine in Patients with Chronic Coronary Disease.
    N Engl J Med. 2021;384:777.
    PubMed    


  84. GEBHARD C, Regitz-Zagrosek V
    Colchicine in Patients with Chronic Coronary Disease.
    N Engl J Med. 2021;384:776-777.
    PubMed    


  85. KAISER D, Jackson CD
    Colchicine in Patients with Chronic Coronary Disease.
    N Engl J Med. 2021;384:776.
    PubMed    


  86. JENKINS DJA, Dehghan M, Mente A, Bangdiwala SI, et al
    Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
    N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2007123.
    PubMed     Abstract available


  87. RODRIGUEZ F, Harrington RA
    Management of Antithrombotic Therapy after Acute Coronary Syndromes.
    N Engl J Med. 2021;384:452-460.
    PubMed    


    January 2021
  88. HUFFMAN MD, Patel A
    Polypills - A Central Strategy for Improving Cardiovascular Health.
    N Engl J Med. 2021;384:288-289.
    PubMed    


  89. SCOTT NS, Thomas SS, DeFaria Yeh D, Fox AS, et al
    Case 2-2021: A 26-Year-Old Pregnant Woman with Ventricular Tachycardia and Shock.
    N Engl J Med. 2021;384:272-282.
    PubMed    


    December 2020
  90. KIM ESH
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2020;383:2358-2370.
    PubMed    


    November 2020
  91. YUSUF S, Joseph P, Dans A, Gao P, et al
    Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028220.
    PubMed     Abstract available


    October 2020
  92. LEE TH
    Seizing the Teachable Moment - Lessons from Eisenhower's Heart Attack.
    N Engl J Med. 2020;383:e100.
    PubMed    


  93. O'GARA PT, Mack MJ
    Secondary Mitral Regurgitation.
    N Engl J Med. 2020;383:1458-1467.
    PubMed    


    September 2020
  94. CANNON CP, Pratley R, Dagogo-Jack S, Mancuso J, et al
    Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
    N Engl J Med. 2020 Sep 23. doi: 10.1056/NEJMoa2004967.
    PubMed     Abstract available


    August 2020
  95. KIRCHHOF P, Camm AJ, Goette A, Brandes A, et al
    Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019422.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: